NCT06797427View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions
Healthy
Interventions
DRUG

DPH001

100 mg

DRUG

Nexavar (Sorafenib)

200 mg

Trial Locations (1)

752 37

Clinical Trial Consultants (CTC), Dag Hammarskjölds väg 10B, Uppsala

Sponsors

Lead Sponsor

Disruptive Pharma
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

lead

Disruptive Pharma

INDUSTRY